KOLMAR BNH Co.,Ltd. (KOSDAQ: 200130)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,250
-250 (-2.17%)
Dec 20, 2024, 9:00 AM KST
-35.38%
Market Cap 327.57B
Revenue (ttm) 619.27B
Net Income (ttm) 15.86B
Shares Out 29.12M
EPS (ttm) 544.70
PE Ratio 20.65
Forward PE n/a
Dividend 308.00 (2.74%)
Ex-Dividend Date n/a
Volume 75,835
Open 11,430
Previous Close 11,500
Day's Range 11,160 - 11,470
52-Week Range 11,030 - 19,970
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 19, 2025

About KOLMAR BNH Co.,Ltd.

Kolmar BNH Co., Ltd. engages in the research and development of materials used in the functional health food and cosmetics market in South Korea and internationally. The company offers cosmetics; and provides total functional health food original development manufacturing services, such as manufacturing tablets, hard capsules, soft capsules, liquids, gels, powder dosage, and various new formulation forms. It offers packaging products, such as PTP/multi-PTP, powder stick/pouch, three-side cloth, four-side, and liquid stick packaging; and ODM con... [Read more]

Industry Perfumes, Cosmetics, and Other Toilet Preparations
Founded 2004
Employees 521
Stock Exchange KOSDAQ
Ticker Symbol 200130
Full Company Profile

Financial Performance

In 2023, KOLMAR BNH Co.,Ltd.'s revenue was 579.55 billion, an increase of 0.63% compared to the previous year's 575.90 billion. Earnings were 19.71 billion, a decrease of -51.35%.

Financial Statements

News

Kolmar BNH Revolutionizes ESG with HemoHIM, an Eco-friendly Health Supplement

SEOUL, South Korea — Kolmar BNH (KRX: 200130), a leading Korean health functional food Original Development Manufacturing (ODM) firm, is at the forefront of Environmental, Social, and Governance (ESG)...

26 days ago - Financial Post

HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA

SEOUL, South Korea — ‘HemoHim,’ an immune-boosting health supplement from Kolmar BNH (KRX: 200130), has earned international recognition for its quality from both the U.S. Food and Drug Administration...

2 months ago - Financial Post